uniQure (QURE)
(Delayed Data from NSDQ)
$5.14 USD
+0.09 (1.78%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $5.15 +0.01 (0.19%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
uniQure N.V. [QURE]
Reports for Purchase
Showing records 1 - 20 ( 155 total )
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Restructuring to Further Streamline Gene Therapy Pipeline; Clarity on Huntington''s Program by End-2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Huntington''s Program Advancing in 2024; Gene Therapy Pipeline Advancing to Phase 1/2
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Huntington''s Program Pathway to Emerge in 2024; Multiple Gene Therapies Advancing to Phase 1/2; Price Target Down to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Year of Execution Should Pave Path Forward For Multiple Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Long-Term AMT-130 Data Shows Clinical Improvement; Disappoints on Target Engagement; Regulatory Path to Emerge in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Hungtington''s Program Phase 1/2 Data Expected in 4Q23; Early Stage Pipeline Progressing to Study Starts
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Restructuring Improves Financial Position Ahead of Next Updates on Huntington''s and Preclinical Gene Therapy Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Clinical Updates on Huntington''s Program Expected in 4Q23; Early-Stage Pipeline Progressing; Lowering PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
AMT-130 Update; Demonstrates Clinical Improvement; Disappoints on Target Engagement; Regulatory Path to Emerge in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Partial Monetization of HEMGENIX Royalties Extends Cash Runway to 2Q26; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Pipeline Progressing; Potential Blockbuster Huntington''s Program Nearing Phase 1/2 Data Update; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
4Q22 Results; HEMGENIX Launch, Key Pipeline Updates on Huntington''s Disease Programs in the Spotlight for 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Read-Through From Pfizer''s Phase 3 Hem-B Data Looks Positive For HEMGENIX
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Spotlight on HEMGENIX at ASH Demonstrates Durable Safety and Efficacy of Treatment in Hem-B; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
HEMGENIX Approved in Hem-B; R&D Event Highlights Platform Progress and Advancement of Epilepsy Program; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Resumes High-Dose AMT-130 Enrollment in Huntington''s Program; EtranaDez on Track for FDA Approval in 4Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Sell-Off Tied to Adverse Events in High Dose Cohort of Huntington''s Program Appears Overdone
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
AMT-130 Demonstrates Robust Target Engagement in Huntington''s Disease Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
1Q22 Results; EtranaDez on Track For Potential Approval in 2023; Next Update on Huntington''s Program Expected in 2Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
4Q21 Results; EtranaDez Nearing Potential Submissions; Huntington''s Program, Preclinical Programs Advancing on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P